In its upcoming report, Labcorp Holdings (LH) is predicted by Wall Street analysts to post quarterly earnings of $4.14 per share, reflecting an increase of 5.1% compared to the same period last year. Revenues are forecasted to be $3.49 billion, representing a year-over-year increase of 8.3%.The consensus EPS estimate for the quarter has undergone a downward revision of 0.1% in the past 30 days, bringing it to its present level. This represents how the covering analysts, as a whole, have reassessed their ini ...

Key Takeaways LH's Q2 revenues are estimated to be $3.49B, up 8.3% year over year, with EPS expected to rise 5.1% to $4.14. Diagnostics growth is driven by acquisitions, partnerships, and expanded specialty lab services. New Alzheimer's and oncology tests likely supported LH's top-line gains in the second quarter.Labcorp Holdings Inc. (LH) , or Labcorp, is slated to report second-quarter 2025 results on July 24, before the opening bell.The renowned laboratory service provider reported adjusted earnings of ...

Looking for a stock that has been consistently beating earnings estimates and might be well positioned to keep the streak alive in its next quarterly report? Labcorp Holdings (LH) , which belongs to the Zacks Medical Services industry, could be a great candidate to consider.This medical laboratory operator has seen a nice streak of beating earnings estimates, especially when looking at the previous two reports. The average surprise for the last two quarters was 2.21%.For the last reported quarter, Labcorp c ...

Wall Street expects a year-over-year increase in earnings on higher revenues when Labcorp Holdings (LH) reports results for the quarter ended June 2025. While this widely-known consensus outlook is important in gauging the company's earnings picture, a powerful factor that could impact its near-term stock price is how the actual results compare to these estimates.The stock might move higher if these key numbers top expectations in the upcoming earnings report, which is expected to be released on July 24. On ...

Core Viewpoint - Labcorp Holdings (LH) has been upgraded to a Zacks Rank 2 (Buy), indicating a positive outlook based on rising earnings estimates, which significantly influence stock prices [1][3]. Earnings Estimates and Stock Price Impact - The Zacks rating system emphasizes the importance of earnings estimate revisions, which are strongly correlated with near-term stock price movements [4][6]. - Institutional investors utilize earnings estimates to determine the fair value of stocks, leading to buying or selling actions that affect stock prices [4]. Labcorp's Earnings Outlook - For the fiscal year ending December 2025, Labcorp is expected to earn $16.05 per share, with a 0.3% increase in the Zacks Consensus Estimate over the past three months [8]. - The upgrade reflects an improvement in Labcorp's underlying business, which is likely to drive the stock price higher as investors respond positively to this trend [5][10]. Zacks Rank System - The Zacks Rank system classifies stocks into five groups based on earnings estimates, with a strong historical performance, particularly for Zacks Rank 1 stocks, which have averaged a +25% annual return since 1988 [7]. - Labcorp's upgrade to Zacks Rank 2 places it in the top 20% of Zacks-covered stocks, suggesting a strong potential for market-beating returns in the near term [9][10].

Albert Anthony is the pen name of a Croatian-American business author who is a media contributor on investor platform Seeking Alpha, where he has over +1K followers, & also writes for platforms like Investing dot com and is launching a book on Amazon in 2025 called Financial Markets: The Next Generation. Calling himself part of the new generation of analysts in the financial markets, he comes from a non-traditional financial background having been an analyst in the IT sector for several Fortune 500 companie ...

Financial Results Announcement - Labcorp Holdings Inc. will release its financial results for the second quarter of 2025 before the market opens on July 24, 2025 [1] - A conference call and webcast will be held at 9 a.m. ET on the same day to discuss the results [1] Webcast Details - The call will be available via live webcast on the Labcorp Investor Relations website, with registration required for dial-in access [2] - Participants are encouraged to join 10 minutes early, but can register and join at any time during the call [2] Replay Information - A replay of the webcast will be accessible approximately two hours after the live event and will remain available until July 11, 2026 [3] Company Overview - Labcorp is a global leader in laboratory services, aiding healthcare professionals and researchers in decision-making [4] - The company employs nearly 70,000 individuals and operates in approximately 100 countries, supporting over 75% of new drugs approved by the FDA in 2024 [4] - Labcorp conducts more than 700 million tests annually for patients worldwide [4]

Core Insights - Labcorp (LH) shares have increased by 25.6% over the past year, outperforming the industry's decline of 16.2% and the S&P 500's gain of 9.1% [1][9] Company Strategy and Growth - Labcorp is focusing on major growth opportunities that are expected to grow faster than other therapeutic areas, supported by a solid pipeline of potential acquisitions [2] - The company is expanding its capabilities in oncology, women's health, autoimmune diseases, and neurology through strategic partnerships and acquisitions [4] - Labcorp has enhanced its testing capabilities for neurodegenerative diseases and launched new solutions in precision oncology, indicating a strong commitment to innovation [5][6] Financial Performance - As of March-end, Labcorp reported cash and cash equivalents of $369 million with zero short-term debt, and a dividend payout ratio of 40.4% after distributing $62 million in dividends [12] - The Zacks Consensus Estimate projects Labcorp's earnings per share (EPS) to increase by 10.2% in 2025 and 9.5% in 2026, with revenues expected to grow by 6.9% to $13.90 billion in 2025 [14] Operational Efficiency - The LaunchPad initiative achieved annual savings of $100-$125 million in 2024, focusing on margin expansion through various operational optimizations [11]

Core Insights - Predictive Oncology Inc. has developed 3D organoid models for Labcorp to enhance drug discovery and preclinical analysis of cancer therapies [1][2][3] - The new models include human and rat liver toxicity models that simulate the liver microenvironment for evaluating drug metabolism and toxicity [2][3] - These organoid models aim to predict in vivo drug clearance, transport, and hepatotoxicity, providing species-specific data that captures hepatic cellular heterogeneity [3][4] Company Developments - The 3D organoid models complement Predictive Oncology's existing AI-driven 2D platform and 3D spheroids, which utilize a biobank of over 150,000 frozen tumor samples [3][6] - The company’s AI platform, PEDAL, predicts with 92% accuracy whether a tumor sample will respond to specific drug compounds, aiding in informed drug selection [6] Industry Trends - The use of organoid-based platforms is seen as a key driver in transforming healthcare, accelerating drug development, and reducing reliance on animal models [4] - There is a growing investment in personalized medicine and biotechnology, with organoids offering cost-effective and high-fidelity alternatives to traditional research methods [4]

Core Insights - Labcorp Holdings Inc. is focusing on key growth areas such as oncology, women's health, autoimmune disease, and neurology, which are expected to drive growth in upcoming quarters [1][3] - The company has a strong balance sheet and a steady pipeline of potential deals that support its financial strategy and enhance organic growth [1][10] - Despite positive growth prospects, macroeconomic volatilities and fierce competition may pose challenges [1][12] Financial Performance - Labcorp's stock has risen 26.5% over the past year, significantly outperforming the industry, which fell by 2.6%, and the S&P 500, which grew by 10.8% [2] - The company has a market capitalization of $20.75 billion and an earnings yield of 6.5%, compared to the industry's 5.9% [2] - Labcorp delivered an average earnings surprise of 2.3% over the trailing four quarters [2] Growth Strategies - The company is enhancing its capabilities in neurodegenerative disease testing with new blood-based biomarkers for Alzheimer's and other neurological conditions [3][4] - In oncology, Labcorp has expanded its offerings with Plasma Detect and received FDA authorization for the PGDx elio plasma focus Dx [4] - Strategic acquisitions, including assets from BioReference Health and North Mississippi Health Services, are aimed at reinforcing Labcorp's leadership in oncology [5][6] Financial Health - Labcorp ended Q1 2025 with cash and cash equivalents of $369 million and no short-term debt, while long-term debt was $5.64 billion [10] - The company returned capital to shareholders through a $62 million dividend payout in Q1, with a dividend payout ratio of 40.4% [11] Market Challenges - Macroeconomic conditions, including inflation and geopolitical tensions, may reduce demand for diagnostic testing and impact profitability [12] - The commercial laboratory sector is highly competitive, with pressures on pricing and service quality affecting Labcorp's market position [13] Future Outlook - The Zacks Consensus Estimate for Labcorp's 2025 earnings is $16.05, with projected revenues of $13.90 billion, indicating a 6.9% improvement from 2024 [14]